Major bleeding in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 105-110

  Holden, Rachel M ^a   Harman, Gavin J ^a   Wang, Miao ^b   Holland, David ^a   Day, Andrew G ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; THROMBOSIS; WARFARIN;

EID: 38749104314     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01810407     Document Type: Article

References (21)

1. Janssen MJ, van der Meulen J: The bleeding risk in chronic haemodialysis: Preventive strategies in high-risk patients. Neth J Med 48: 198-207, 1996
2. Miller LM, Hopman WM, Garland JS, Yeates KE, Pilkey RM: Cardioprotective medication use in hemodialysis patients. Can J Cardiol 22: 755-760, 2006
3. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87: 144-152, 1989
4. Crowther MA, Clase CM, Margetts PJ, Julian J, Lambert K, Sneath D, Nagai R, Wilson S, Ingram AJ: Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 13: 2331-2337, 2002
5. Mokrzycki NIH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO: A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 59: 1935-1942, 2001
6. Calverley DC, Roth GJ: Antiplatelet therapy: Aspirin, ticlopidine/ clopidogrel, and anti-integrin agents. Hematol Oncol Clin North Am 12: 1231-1249, vi, 1998
7. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN, Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313-2321, 2003
8. Domoto DT, Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 62: 737-743, 1991
9. Buchanan MR, Hirsh J: Effect of aspirin on hemostasis and thrombosis. N Engl Reg Allergy Proc 7: 26-31, 1986
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987
11. Biggers JA, Remmers AR Jr, Glassford DM, Sarles HE, Lindley JD, Fish JC: The risk of anticoagulation in hemodialysis patients. Nephron 18: 109-113, 1977
12. Vazquez E, Sanchez-Perales C, Garcia-Cortes Mj, Borrego F, Lozano C, Guzman M, Gil JM, Liebana A, Perez P, Borrego MJ, Perez V: Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol 87: 135-139, discussion 139-141, 2003
13. Zellweger M, Bouchard J, Raymond-Carrier S, Laforest-Renald A, Querin S, Madore F: Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J 51: 360-365, 2005
14. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154: 1449-1457, 1994 [published erratum appears in Arch Intern Med 154: 2254, 1994]
15. O'Shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL: Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38: 541-548, 2003
16. LeSar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 189: 73-79, discussion 79-81, 1999
17. Landefeld CS, Beyth RJ: Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 95: 315-328, 1993
18. Vazquez E, Sanchez-Perales C, Borrego F, Garcia-Cortes Mj, Lozano C, Guzman M, Gil JM, Borrego MJ, Perez V: Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 140: 886-890, 2000
19. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P: Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 21: 35-39, 2001
20. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 301: 577-579, 1979
21. Obialo CI, Conner AC, Lebon LF: Maintaining patency of tunneled hemodialysis catheters: Efficacy of aspirin compared to warfarin. Scand J Urol Nephrol 37: 172-176, 2003